-
公开(公告)号：US20230082516A1
公开(公告)日：2023-03-16
申请号：US17417201
申请日：2020-01-07
发明人： Shigeki SETO , Hitomi YAMADA , Yoshifumi SAITO , Haruaki KURASAKI
IPC分类号： C07D265/36 , C07D267/02 , C07D267/22 , C07D498/04 , C07D281/02 , C07D519/00 , C07D279/16 , C07D471/04
摘要： [Problem]
To provide a compound having a 15-PGDH inhibitory effect.
[Solution]
A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.-
公开(公告)号：US20210187510A1
公开(公告)日：2021-06-24
申请号：US17270848
申请日：2019-08-29
申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY , KYORIN PHARMACEUTICAL CO., LTD.
发明人： Hidenori NAGAI , Shunsuke FURUTANI , Hideyasu KUBO
摘要： A PCR vessel having: a substrate, a flow channel formed in the substrate, a pair of filters provided at both ends of the flow channel, a pair of air communication ports communicating with the flow channel through the filters, a thermal cycle region formed between the pair of filters in the flow channel, and a sample injection port through which a sample can be injected into the flow channel from above; wherein the sample injection port in the surface of the substrate has an area of 0.7 to 1.8 mm2.
-
公开(公告)号：US20210107869A1
公开(公告)日：2021-04-15
申请号：US16880443
申请日：2020-05-21
IPC分类号： C07D207/273 , C07D403/12 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D413/12 , C07D417/12 , C07D209/54 , C07D405/14 , C07D413/14 , C07D401/06 , C07D403/04 , C07D409/14 , C07D413/06 , C07D207/22
摘要： Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect.
The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.-
公开(公告)号：US20210000831A1
公开(公告)日：2021-01-07
申请号：US16768972
申请日：2018-12-20
发明人： Katsuya SEGAWA , Takafumi KUROSE
IPC分类号： A61K31/519 , A61P13/10
摘要： [Problem] To provide a novel therapeutic agent for nocturnal pollakiuria.
[Solution] A therapeutic agent for nocturnal pollakiuria which contains, as an active ingredient, (6S)—N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide.-
公开(公告)号：US10154993B2
公开(公告)日：2018-12-18
申请号：US15519917
申请日：2015-10-23
IPC分类号： A61K31/4709 , A61K47/02 , A61K47/26 , A61K9/16 , A61K9/20
摘要： [Problem] To provide a novel pharmaceutical composition which can suppress delayed, release of the compound represented in general formula (1) or a salt thereof.[Solution] This solid pharmaceutical composition contains the compound represented in general formula (1), or a salt thereof, and a salting-out agent.
-
公开(公告)号：US20180208552A1
公开(公告)日：2018-07-26
申请号：US15576345
申请日：2016-05-26
发明人： Hiroyasu TAKAHASHI , Hiroyuki WATANABE , Kiyoshi FUJII , Mitsuhito SHIBASAKI , Mikako KAWASHIMA , Megumi KAMIYA , Kohei OHATA
IPC分类号： C07C275/30 , C07C275/42 , C07C275/50 , C07D231/12 , C07D285/08 , C07D285/135 , C07D271/113 , C07D271/07 , C07D239/36 , A61P29/00 , A61P35/00 , A61P31/18
CPC分类号： C07C275/30 , A61P29/00 , A61P31/18 , A61P35/00 , C07B2200/07 , C07C275/42 , C07C275/50 , C07C311/51 , C07C317/32 , C07C317/40 , C07C2601/02 , C07D213/61 , C07D231/12 , C07D239/36 , C07D249/04 , C07D249/08 , C07D249/12 , C07D257/04 , C07D261/08 , C07D263/32 , C07D263/34 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/113 , C07D273/04 , C07D277/28 , C07D285/08 , C07D285/12 , C07D285/135 , C07D307/79 , C07D311/58 , C07D333/16 , C07D333/28 , C07D413/04 , C07D413/12 , C07D417/12
摘要： The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
-
公开(公告)号：US20180147199A1
公开(公告)日：2018-05-31
申请号：US15578764
申请日：2016-06-02
发明人： Wataru MINAGAWA , Hitoshi KOZUKA , Mizuho SHIBATA , Takahiro GOTO , Chifuyu TORIUMI , Norihiro KANAYAMA
IPC分类号： A61K31/4709 , A61K47/02 , A61P31/04 , A61K9/08
CPC分类号： A61K31/4709 , A61K9/08 , A61K47/02 , A61P31/04
摘要： A novel technique with which it is possible to suppress chemical degradation of a compound represented by general formula (1) or a salt thereof in an aqueous liquid formulation containing a compound represented by general formula (1) or a salt thereof. A method for suppressing the generation of a compound represented by general formula (2) or a salt thereof including containing a compound represented by general formula (1) or a salt thereof and a magnesium compound in an aqueous liquid formulation.
-
公开(公告)号：US09822069B2
公开(公告)日：2017-11-21
申请号：US15039964
申请日：2014-11-27
IPC分类号： C07D207/273 , C07D209/54 , C07D417/12 , C07D207/22 , C07D409/04 , C07D401/04 , C07D413/12 , C07D413/14 , C07D403/12 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D405/14 , C07D401/06 , C07D403/04 , C07D409/14 , C07D413/06
CPC分类号： C07D207/273 , C07D207/22 , C07D209/54 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect.The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.
-
公开(公告)号：US20170319571A1
公开(公告)日：2017-11-09
申请号：US15519917
申请日：2015-10-23
IPC分类号： A61K31/4709 , A61K47/02 , A61K9/20 , A61K47/26 , A61K9/16
CPC分类号： A61K31/4709 , A61K9/16 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2095 , A61K47/02 , A61K47/26
摘要： [Problem] To provide a novel pharmaceutical composition which can suppress delayed, release of the compound represented in general formula (1) or a salt thereof.[Solution] This solid pharmaceutical composition contains the compound represented in general formula (1), or a salt thereof, and a salting-out agent.
-
公开(公告)号：US09216163B2
公开(公告)日：2015-12-22
申请号：US14196247
申请日：2014-03-04
发明人： Keizo Sato , Tomohiro Shinya , Shiori Nakayama
IPC分类号： A61K31/195 , A61K31/198
CPC分类号： A61K31/198 , A61K31/195
摘要： A novel angiogenesis inhibitor, and a method for inhibiting angiogenesis are provided. Also provided are a prophylactic or therapeutic agent for a disease accompanied by angiogenesis, and a method for preventing or treating a disease accompanied by angiogenesis. The angiogenesis inhibitor contains L-carbocisteine or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要翻译： 提供了一种新型的血管生成抑制剂和抑制血管发生的方法。 还提供了伴随血管发生的疾病的预防或治疗剂，以及用于预防或治疗伴有血管生成的疾病的方法。 血管生成抑制剂含有L-胆甾醇或其药学上可接受的盐作为活性成分。
-
-
-
-
-
-
-
-
-
搜索结果
236 条记录 (耗时 0.049 秒)
